From: Third generation EGFR TKIs: current data and future directions
Third Generation EGFR TKI | Status of development | Trial | Dose | n | ORR | PFS (mth) (95% CI) | Adverse events (selected all grade) |
---|---|---|---|---|---|---|---|
Osimertinib (AZD9291) | Approved for T790 M mutation post EGFR TKI | AURA 3 NCT01802632 | 80 mg daily | 279 | 71% (65–76%) | 10.1 (8.3–12.3) | Diarrhea (41%); rash (34%), paronychia (22%); pneumonitis (4%) |
Olmutinib | Developing in Korea | NCT01588145 | 800 mg daily | 76 | 56% | 7.0 (5.5–8.3) | Diarrhea (55%), rash (39%), nauseas (38%). |
Nazartinib (EGF816) | Phase I/II | NCT02108964 | 75-350Â mg QD | 132 | 44% | 9.2 (9.0-NE) | Diarrhea (40%), maculopapular rash (39%), pruritus (32%), stomatitis (23%), and fatigue (21%). |
Avitinib (AC0010) | Phase I/II (phase II AEGIS-1 trial had started) | NCT02330367 | 50-350Â mg BID 150-300Â mg cohort | 136 95 | 44% a 51% | NA | Diarrhea (38%) and rash (24%) |